Selective thyromimetics for atherosclerosis and dyslipidaemia: another old target making progress

Whereas many new targets for drug discovery have been identified from new biology, such as that from the Human Genome Project, some targets have been known for decades but have not been exploited. One such target, selective thyromimetics, is reviewed from a historical perspective and in the light of...

Full description

Saved in:
Bibliographic Details
Published inExpert opinion on investigational drugs Vol. 17; no. 5; p. 615
Main Author Suckling, Keith
Format Journal Article
LanguageEnglish
Published England 01.05.2008
Subjects
Anilides - chemistry
Anilides - pharmacology
Anilides - therapeutic use
Atherosclerosis - drug therapy
Drug Design
Dyslipidemias - drug therapy
Humans
Molecular Structure
Thyroid Hormones - chemistry
Thyroid Hormones - pharmacology
Thyroid Hormones - physiology
Online AccessGet more information

Cover

More Information
Summary:Whereas many new targets for drug discovery have been identified from new biology, such as that from the Human Genome Project, some targets have been known for decades but have not been exploited. One such target, selective thyromimetics, is reviewed from a historical perspective and in the light of recent developments. The history of thyromimetics in atherosclerosis and dyslipidaemia is reviewed as the background to the recent publication of the first human data on a new selective thyromimetic, KB-2115 (eprotirome). The published data provide proof of concept/mechanism, opening the way to larger studies in a wider range of subjects and in combination with statins.
ISSN:1744-7658
DOI:10.1517/13543784.17.5.615